Evidence map›Paper›PMID 29792216›Full record

ArticleRetrovirology2018

HIV-1 Tat phosphorylation on Ser-16 residue modulates HIV-1 transcription.

Andrey Ivanov, Xionghao Lin, Tatiana Ammosova, Andrey V Ilatovskiy, Namita Kumari, Hatajai Lassiter, Nowah Afangbedji, Xiaomei Niu, Michael G Petukhov, Sergei Nekhai

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. HIV Transcription Is Independent of Mediator Kinases.AIDS research and human retroviruses · 2019
    Article
  11. Review
  12. Genetic variation and function of the HIV-1 Tat protein.Medical microbiology and immunology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Andrey IvanovCenter for Sickle Cell Disease, Howard University, 1840 7th Street, N.W. HURB1, Suite 202, Washington, DC, 20001, USA.
Xionghao LinCenter for Sickle Cell Disease, Howard University, 1840 7th Street, N.W. HURB1, Suite 202, Washington, DC, 20001, USA.
Tatiana AmmosovaCenter for Sickle Cell Disease, Howard University, 1840 7th Street, N.W. HURB1, Suite 202, Washington, DC, 20001, USA.
Andrey V IlatovskiyDivision of Molecular and Radiation Biophysics, Petersburg Nuclear Physics Institute, Gatchina, Russia.
Namita KumariCenter for Sickle Cell Disease, Howard University, 1840 7th Street, N.W. HURB1, Suite 202, Washington, DC, 20001, USA.
Hatajai LassiterCenter for Sickle Cell Disease, Howard University, 1840 7th Street, N.W. HURB1, Suite 202, Washington, DC, 20001, USA.
Nowah AfangbedjiCenter for Sickle Cell Disease, Howard University, 1840 7th Street, N.W. HURB1, Suite 202, Washington, DC, 20001, USA.
Xiaomei NiuCenter for Sickle Cell Disease, Howard University, 1840 7th Street, N.W. HURB1, Suite 202, Washington, DC, 20001, USA.
Michael G PetukhovDivision of Molecular and Radiation Biophysics, Petersburg Nuclear Physics Institute, Gatchina, Russia.
Sergei NekhaiCenter for Sickle Cell Disease, Howard University, 1840 7th Street, N.W. HURB1, Suite 202, Washington, DC, 20001, USA. snekhai@howard.edu.ORCID 0000-0003-0744-7887
Howard University · USPeter the Great St. Petersburg Polytechnic University · RU

Funding

SWG 2: Cure Research Scientific Working GroupP30AI117970 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI MICHAEL Ilya BUKRINSKY · 2015 to 2026
$29.6M
Therapeutics Targeting Filoviral interferon-antagonist and replication functionsU19AI109664 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BASLER, CHRISTOPHER F · 2014 to 2018
$15.8M
PROTEOMICS CORE FACILITYG12MD007597 · NIMHD · HOWARD UNIVERSITY · PI SOUTHERLAND, WILLIAM M. · 2012 to 2018
$14.8M
Center for Hemoglobin Research in Minorities (CHaRM)P50HL118006 · NHLBI · HOWARD UNIVERSITY · PI NEKHAI, SERGEI · 2013 to 2017
$7.0M
Sickle Cell Disease and Sickle Cell Trait Protection Against HIV-1-infection in Africans and African AmericansR01HL125005 · NHLBI · HOWARD UNIVERSITY · PI MARINA A JEREBTSOVA, SERGEI NEKHAI · 2014 to 2026
$6.7M
Ministry of Education and Science of the Russian Federation 2012-1.5-12-000-1001-030National Institute of Allergy and Infectious Diseases AI117970National Institute of Allergy and Infectious Diseases U19AI109664NHLBI NIH HHS P50 HL118006NHLBI NIH HHS P50HL118006NHLBI NIH HHS R01 HL125005NHLBI NIH HHS R01HL125005NIAID NIH HHS P30 AI117970NIAID NIH HHS U19 AI109664NIMHD NIH HHS 5G12MD007597NIMHD NIH HHS G12 MD007597Russian Foundation for Basic Research 12-04-91444-NIZ
6 · The paper itself

Abstract

backgroundHIV-1 transcription activator protein Tat is phosphorylated in vitro by CDK2 and DNA-PK on Ser-16 residue and by PKR on Tat Ser-46 residue. Here we analyzed Tat phosphorylation in cultured cells and its functionality.

resultsMass spectrometry analysis showed primarily Tat Ser-16 phosphorylation in cultured cells. In vitro, CDK2/cyclin E predominantly phosphorylated Tat Ser-16 and PKR-Tat Ser-46. Alanine mutations of either Ser-16 or Ser-46 decreased overall Tat phosphorylation. Phosphorylation of Tat Ser-16 was reduced in cultured cells treated by a small molecule inhibitor of CDK2 and, to a lesser extent, an inhibitor of DNA-PK. Conditional knock-downs of CDK2 and PKR inhibited and induced one round HIV-1 replication respectively. HIV-1 proviral transcription was inhibited by Tat alanine mutants and partially restored by S16E mutation. Pseudotyped HIV-1 with Tat S16E mutation replicated well, and HIV-1 Tat S46E-poorly, but no live viruses were obtained with Tat S16A or Tat S46A mutations. TAR RNA binding was affected by Tat Ser-16 alanine mutation. Binding to cyclin T1 showed decreased binding of all Ser-16 and Ser-46 Tat mutants with S16D and Tat S46D mutationts showing the strongest effect. Molecular modelling and molecular dynamic analysis revealed significant structural changes in Tat/CDK9/cyclin T1 complex with phosphorylated Ser-16 residue, but not with phosphorylated Ser-46 residue.

conclusionPhosphorylation of Tat Ser-16 induces HIV-1 transcription, facilitates binding to TAR RNA and rearranges CDK9/cyclin T1/Tat complex. Thus, phosphorylation of Tat Ser-16 regulates HIV-1 transcription and may serve as target for HIV-1 therapeutics.

Indexed as

Gene Expression Regulation, ViralTranscription, GeneticAmino Acid SequenceCells, CulturedCyclin-Dependent Kinase 2Cyclin-Dependent Kinase 9Cyclin TeIF-2 KinaseGene Knockdown TechniquesHIV-1HIV InfectionsHost-Pathogen InteractionsHumansModels, BiologicalModels, MolecularMutationCDK2 protein, humanCDK9 protein, humanCyclin-Dependent Kinase 2Cyclin-Dependent Kinase 9Cyclin TEIF2AK2 protein, humaneIF-2 KinaseRNA, ViralSerinetat Gene Products, Human Immunodeficiency Virus

Identifiers

PMID29792216
PMCPMC5966876
OpenAlexW2805911498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.